全文获取类型
收费全文 | 99篇 |
免费 | 1篇 |
专业分类
基础医学 | 22篇 |
临床医学 | 17篇 |
内科学 | 32篇 |
神经病学 | 3篇 |
外科学 | 18篇 |
预防医学 | 6篇 |
药学 | 2篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 3篇 |
2013年 | 1篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 2篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 3篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 1篇 |
1997年 | 1篇 |
1980年 | 2篇 |
排序方式: 共有100条查询结果,搜索用时 15 毫秒
61.
Ananworanich J Gayet-Ageron A Le Braz M Prasithsirikul W Chetchotisakd P Kiertiburanakul S Munsakul W Raksakulkarn P Tansuphasawasdikul S Sirivichayakul S Cavassini M Karrer U Genné D Nüesch R Vernazza P Bernasconi E Leduc D Satchell C Yerly S Perrin L Hill A Perneger T Phanuphak P Furrer H Cooper D Ruxrungtham K Hirschel B;Staccato Study Group;Swiss HIV Cohort Study 《Lancet》2006,368(9534):459-465
62.
Boyd M Mootsikapun P Burger D Chuenyam T Ubolyam S Mahanontharit A Sangkote J Bunyaprawit P Horsakulchai M Lange J Cooper D Phanuphak P Ruxrungtham K 《Antiviral therapy》2005,10(2):301-307
OBJECTIVE: To study the pharmacokinetics of indinavir/ ritonavir 400/100 mg twice daily in antiretroviral-naive patients at Srinagarind Hospital in Khon Kaen, Thailand. METHODS: This was a steady-state, open-label pharmacokinetic study of 19 patients. A 12 h pharmacokinetic curve was recorded after an overnight fast. Plasma levels of indinavir and ritonavir were determined by a validated HPLC method. Virological failure was defined according to the most recent US Department of Health and Human Services guidelines as a viral load above 400 copies/ml at week 24. RESULTS: Median baseline values for CD4 and viral load were 13cells/mm3 and 167000 copies/ml, respectively. The median (interquartile ranges) for indinavir AUC, Cmax and Cmin were 18.1 (15.3-23.8) mg/l x h, 4.1 (3.6-4.8) mg/l and 0.17 (0.12-0.30) mg/l, respectively. These values represent 37%, 39% and 24% of the AUC, Cmax and Cmin values found, respectively, for the indinavir/ritonavir 800/100 mg dose in HIV-1-infected Thai patients. Short-term virological response was satisfactory. There were three subjects with an indinavir Cmin. below the target value of 0.10 mg/l, of whom one had virological failure (33%). Among the other 16 subjects with an indinavir Cmin above 0.10 mg/l, there was also one virological failure (6%) (P=0.30). CONCLUSIONS: Indinavir exposure in this reduced-dose regimen of 400 mg with 100 mg ritonavir twice daily was more than dose-proportionally lower than previously observed with the indinavir/ritonavir 800/100 mg twice daily regimen. Therapeutic Cmin levels of indinavir were achieved in >80% of the subjects and short-term virological response was satisfactory in this cohort of patients starting highly active antiretroviral therapy at an advanced disease stage with high baseline viral loads. 相似文献
63.
Reshmie A Ramautarsing Ratchadaporn Meksena Thanthip Sungsing Tanat Chinbunchorn Theeranat Sangprasert Orawan Fungfoosri Dusita Meekrua Saman Sumalu Thapana Pasansai Witwasin Bunainso Tashada Wongsri Nuttakrit Mainoy Donn Colby Matthew Avery Stephen Mills Ravipa Vannakit Praphan Phanuphak Nittaya Phanuphak 《Journal of the International AIDS Society》2020,23(Z3)
64.
Autar RS Boyd MA Wit FW Ruxrungthams K Sankote J Lange J Cooper DA Phanuphak P Burger DM Reiss P 《Antiviral therapy》2007,12(8):1265-1271
BACKGROUND: The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood. METHODS: Relationships between fasted metabolic parameters, body composition, and drug plasma concentrations were investigated in 59 patients who switched from failed nucleoside analogue treatment to ritonavir-boosted indinavir and efavirenz therapy. Metabolic parameters, peripheral fat, visceral adipose tissue (VAT) and drug plasma concentrations were measured prospectively. RESULTS: Ritonavir exposure was found to be negatively correlated with high-density lipoprotein cholesterol (HDL-c) changes, with a 2.4% decrease in HDL-c for each unit increase in ritonavir concentration ratio. Significant associations between indinavir or efavirenz concentrations and metabolic disturbances were not observed. Total cholesterol (TC) correlated positively with high body mass index (BMI) and negatively with baseline limb fat mass: each unit increase in BMI and each kilogram reduction in baseline limb fat corresponded with a TC increase of 2.4% and 4.1%, respectively. Baseline triglyceride levels were lower in those patients with relatively greater limb fat mass: each kilogram reduction of total limb fat mass was associated with a 15.7% increase in triglyceride concentration. Changes in VAT were positively correlated with TC: for every unit TC increase a 0.3% VAT increase was observed (over 48 weeks). CONCLUSIONS: Reduced limb fat mass at the start of the study treatment, increases in VAT mass, and higher plasma concentrations of ritonavir on study treatment were each--to varying degrees--associated with various metabolic disturbances. 相似文献
65.
Jay K. Varma Kimberly D. McCarthy Theerawit Tasaneeyapan Patama Monkongdee Michael E. Kimerling Eng Buntheoun Delphine Sculier Chantary Keo Praphan Phanuphak Nipat Teeratakulpisarn Nibondh Udomsantisuk Nguyen H. Dung Nguyen T.N. Lan Nguyen T.B. Yen Kevin P. Cain 《Emerging infectious diseases》2010,16(10):1569-1575
Bloodstream infections (BSIs) are a major cause of illness in HIV-infected persons. To evaluate prevalence of and risk factors for BSIs in 2,009 HIV-infected outpatients in Cambodia, Thailand, and Vietnam, we performed a single Myco/F Lytic blood culture. Fifty-eight (2.9%) had a clinically significant BSI (i.e., a blood culture positive for an organism known to be a pathogen). Mycobacterium tuberculosis accounted for 31 (54%) of all BSIs, followed by fungi (13 [22%]) and bacteria (9 [16%]). Of patients for whom data were recorded about antiretroviral therapy, 0 of 119 who had received antiretroviral therapy for >14 days had a BSI, compared with 3% of 1,801 patients who had not. In multivariate analysis, factors consistently associated with BSI were fever, low CD4+ T-lymphocyte count, abnormalities on chest radiograph, and signs or symptoms of abdominal illness. For HIV-infected outpatients with these risk factors, clinicians should place their highest priority on diagnosing tuberculosis.Bloodstream infections (BSIs) are a major cause of illness in HIV-infected persons. A series of studies, most of which were conducted in sub-Saharan Africa during the 1990s, demonstrated a high prevalence of BSIs (ranging from 10% to 63%) among hospitalized HIV-infected persons who had fever (1–17). In studies that measured clinical outcomes, the in-hospital death rate for patients with a BSI was high (19%–47%). A variety of pathogens cause BSIs in febrile, hospitalized persons with HIV, most notably non-Typhi Salmonella spp. (6%–15%) and Mycobacterium tuberculosis (2%–19%). BSI with M. tuberculosis appears to be particularly lethal, causing death during hospitalization in up to 47% of patients (9). Although untreated BSIs are believed to lead rapidly to severe illness, sepsis, and death, patients with BSIs may be able to be identified before they are ill enough to require hospitalization, potentially improving clinical outcomes. Despite the large number of studies that have evaluated BSIs in HIV-infected persons, all previous studies have focused on patients seeking care at hospitals because of fever and did not evaluate infections among outpatients with or without fever.Although overall transmission rates have declined and antiretroviral therapy (ART) has become more widely available, HIV infection remains a major public health problem in Southeast Asia (18). Previous studies of BSI in Southeast Asia enrolled only inpatients, and only 1 evaluated a predominantly HIV-infected population (1,19–21). In this study, we prospectively enrolled patients from multiple HIV testing and treatment clinics in Cambodia, Thailand, and Vietnam to assess BSI prevalence, etiology, and risk factors in outpatients with HIV. 相似文献
66.
Michael J Peluso Donn J Colby Suteeraporn Pinyakorn Sasiwimol Ubolyam Jintana Intasan Rapee Trichavaroj Nitiya Chomchey Peeriya Prueksakaew Bonnie M Slike Shelly J Krebs Ningbo Jian Merlin L Robb Praphan Phanuphak Nittaya Phanuphak Serena Spudich Jintanat Ananworanich Eugne Kroon 《Journal of the International AIDS Society》2020,23(1)
67.
Thomas E. Guadamuz Wipas Wimonsate Anchalee Varangrat Praphan Phanuphak Rapeepun Jommaroeng Philip A. Mock Jordan W. Tappero Frits van Griensven 《Archives of sexual behavior》2011,40(2):259-266
Although forced sex is a correlate of HIV infection, its prevalence and associated risks are not well described among men
who have sex with men (MSM) in developing-country settings. Between March and October 2005, we assessed the prevalence of
forced sex and correlates among populations of MSM (this includes general MSM, male sex workers, and male-to-female transgender
persons) in Thailand using a community-based sample. Participants were enrolled from venues around Bangkok, Chiangmai, and
Phuket using venue day-time sampling. Handheld computer-assisted self-interviewing was used to collect demographic and behavioral
data and logistic regression evaluated factors associated with forced sex, defined as ever being forced to have sexual intercourse
against one’s will. Of the 2,049 participants (M age, 24.8 years), a history of forced sex was reported by 376 (18.4%) men and, of these, most were forced by someone they
knew (83.8%), forced more than once (67.3%), and had first occurrence during adolescence (55.1%). In multivariate analysis,
having a history of forced sex was significantly associated with being recruited in Phuket, classification as general MSM
or transgender (versus classification as male sex worker), drug use, increased number of male sexual partners, and buying
sex. The findings in our assessment were consistent with assessments from Western countries. Longitudinal studies are needed
to understand the mechanisms of the relationships between forced sex correlates found in our assessment and HIV acquisition
and transmission risks. 相似文献
68.
Ramautarsing RA van der Lugt J Gorowara M Wongsabut J Khongpetch C Phanuphak P Ananworanich J Lange JM Burger DM Ruxrungtham K Avihingsanon A 《Journal of acquired immune deficiency syndromes (1999)》2012,59(1):55-58
We assessed pharmacokinetic (PK) parameters of reduced dose lopinavir/ritonavir (LPV/r) and compared generic and branded tablets. Twenty HIV-infected patients using protease inhibitors with HIV RNA <50 copies per milliliter were randomized to generic or branded LPV/r 200/50mg twice daily (BID). At week 2, PK-sampling was performed. Patients crossed over to the other arm until week 12, with another PK-sampling at week 4. Subtherapeutic lopinavir concentrations were observed in 10/40 samples. PK parameters were comparable between branded and generic tablets. All patients remained virologically suppressed at week 12. In conclusion, LPV/r 200/50mg BID does not lead to adequate lopinavir plasma concentrations. Generic and branded LPV/r have comparable PK-parameters. 相似文献
69.
Wichittra Tassaneeyakul Somsak Tiamkao Thawinee Jantararoungtong Pei Chen Shu‐Yi Lin Wei‐Hsuan Chen Parinya Konyoung Usanee Khunarkornsiri Narong Auvichayapat Kasemsin Pavakul Kongkiat Kulkantrakorn Charoen Choonhakarn Siranun Phonhiamhan Namfon Piyatrakul Thiti Aungaree Sunsanee Pongpakdee Praphan Yodnopaglaw 《Epilepsia》2010,51(5):926-930
Carbamazepine (CBZ) has been reported as the most common culprit drug for Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in several Asian countries including Thailand. A strong association between HLA‐B*1502 and CBZ‐induced SJS/TEN has been reported in Han Chinese but not in Caucasian and Japanese populations. A case–control study was conducted to determine whether HLA‐B*1502 is a valid pharmacogenetic test for SJS/TEN caused by CBZ in a Thai population. Among 42 CBZ‐induced patients with SJS/TEN, 37 (88.10%) patients carried the HLA‐B*1502 while only 5 (11.90%) of the CBZ‐tolerant controls had this allele. The risk of CBZ‐induced SJS/TEN was significantly higher in the patients with HLA‐B*1502, with an odds ratio (OR) of 54.76 [95% confidence interval (CI) 14.62–205.13, p = 2.89 × 10?12]. The sensitivity and specificity of HLA‐B*1502 for prediction of CBZ‐induced SJS/TEN were 88.10%. By assuming a 0.27% as a prevalence rate of CBZ‐induced SJS/TEN in a Thai population, the positive predictive value (PPV) and negative predictive value (NPV) of the HLA‐B*1502 were 1.92% and 99.96%. Results from this study suggest that HLA‐B*1502 may be a useful pharmacogenetic test for screening Thai individuals who may be at risk for CBZ‐induced SJS and TEN. 相似文献
70.
Autar RS Wit FW Sankote J Sutthichom D Kimenai E Hassink E Hill A Cooper DA Phanuphak P Lange JM Burger DM Ruxrungtham K 《AIDS (London, England)》2007,21(12):1535-1539
OBJECTIVE: To improve the pharmacokinetics of protease inhibitors, boosting with low-dose ritonavir is performed. However, toxicity, storage conditions and high costs of antiretroviral treatment may necessitate interruption of ritonavir. Ketoconazole was investigated as a potential booster of once-daily (o.d.) saquinavir. METHODS: In a single-group, two-period design, 25 virologically and immunologically stable patients on saquinavir/ritonavir 2000/100 mg o.d. were switched to saquinavir/ketoconazole 2000/400 mg o.d. for 2 weeks. Two steady-state pharmacokinetic curves were recorded at both periods. RESULTS: Fourteen females and 11 male patients were included. Median age was 34 years [interquartile range (IQR), 32-42 years], body weight 54 kg (IQR, 47-59 kg) and body mass index 21 kg/m (19-23 kg/m). The mean saquinavir area under the curve (AUC) during boosting with ritonavir was 57.93 +/- 27.96 mg/h/l, maximum observed concentration (Cmax) was 7.50 +/- 3.45 mg/l and concentration at 24 h (Cmin) was 0.35 +/- 0.30 mg/l. When ketoconazole was used, the saquinavir AUC, Cmax, and Cmin were 12.00 +/- 6.97 mg/h/l, 2.43 +/- 1.35 mg/l and 0.03 +/- 0.04 mg/l, respectively. CONCLUSION: Boosting with ketoconazole resulted in 80% lower exposure to saquinavir. Although saquinavir AUC might still be adequate for treatment, concentrations at 24 h reached levels below the recommended trough concentrations of 0.1 mg/l, which may result in selection of resistant HIV-1 viral strains. Therefore, boosting of saquinavir by ketoconazole is not recommended. 相似文献